TREMFYA® is the first FDA-approved medication of its kind to selectively block IL-23 for adults with moderate to severe plaque psoriasis.
Uncover results with TREMFYA®
With only 6 maintenance doses of TREMFYA®, every 8 weeks, after two starter doses at weeks 0 and 4.
Individual results may vary.
For adults with moderate to severe plaque psoriasis
CLEARER SKIN THAT CAN LAST
In clinical studies, at 16 weeks, at least 7 out of 10 patients saw at least 90% clearer skin, and more than 8 out of 10 were rated clear or almost clear.
In a clinical study, nearly 9 out of 10 people who saw 90% clearer skin at 28 weeks continued to see 90% clearer skin at 48 weeks.
In a study, the majority of TREMFYA® patients saw 90% clearer skin at nearly 4 years. At 1 year and thereafter, patients knew they were getting TREMFYA®, which may affect results. Results may vary.
*At week 204.
In one clinical study, 5 out of 10 patients saw completely clear skin.
In clinical studies at week 16, 4 out of 5 people with scalp psoriasis were rated clear or almost clear of their scalp psoriasis.
IMPROVED SYMPTOMS AT 16 WEEKS
In clinical studies at 16 weeks, patients had improvements in symptoms of plaque psoriasis including itching, burning, pain, stinging, and skin tightness.
SUPERIOR SKIN CLEARANCE
In clinical studies, TREMFYA® worked better than Humira® (adalimumab) at providing significantly clearer skin.
Results are reflective of patients studied in the United States and Canada.
Humira® is a registered trademark of AbbVie Inc.
Individual results may vary.
Ask your doctor about the benefits and risks of TREMFYA®. Prescription medications, including TREMFYA®, have possible risks involved with treatment, so it’s important to discuss them with your doctor.
TREMFYA may cause serious side effects, including:
Serious allergic reactions. Stop using TREMFYA and get emergency medical help right away if you develop any of the following symptoms of a serious allergic reaction:
- fainting, dizziness, feeling lightheaded (low blood pressure)
- swelling of your face, eyelids, lips, mouth, tongue or throat
- trouble breathing or throat tightness
- chest tightness
- skin rash, hives
- Infections. TREMFYA is a medicine that may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with TREMFYA and may treat you for TB before you begin treatment with TREMFYA if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with TREMFYA.
Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including:
- fever, sweats, or chills
- shortness of breath
- blood in your phlegm (mucus)
- muscle aches
- warm, red, or painful skin or sores on your body different from your psoriasis
- weight loss
- diarrhea or stomach pain
- burning when you urinate or urinating more often than normal
These are not all the possible side effects of TREMFYA.
Please read the Important Safety Information located at the bottom of the screen and the Medication Guide for TREMFYA to learn more about these and other risks for TREMFYA. Discuss any questions you have with your doctor.
TREMFYA may cause serious side effects including:
- See “What is the most important information I should know about TREMFYA?"
The most common side effects of TREMFYA include:
- upper respiratory infections
- joint pain (arthralgia)
- fungal skin infections
- herpes simplex infections
- injection site reactions
- stomach flu (gastroenteritis)
These are not all the possible side effects of TREMFYA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.